Paper 67 - NRG-DT001 PHASE IB TRIAL OF NEOADJUVANT NAVTEMADLIN AND RADIOTHERAPY IN TP53 WILD-TYPE SOFT TISSUE SARCOMA: PRELIMINARY EFFICACY ANALYSIS

Author(s)

• 

  Meng Welliver, MD, Ph.D

  Senior Associate Consultant
  Mayo Clinic
  Rochester, Minnesota, United States

  Slides

Co-Author(s)

• JH

  Jonathan Harris, MS

  NRG Oncology
  Philadelphia, Pennsylvania, United States
• DG

  Dominique Garrison, Ph.D

  Johns Hopkins University
  Baltimore, Maryland, United States
• PH

  Peter Houghton, Ph.D

  Professor
  UT Health San Antonio
  San Antonio, Texas, United States
• 

  David G. Kirsch, M.D., Ph.D.

  Senior Scientist
  Princess Margaret Cancer Centre
  Toronto, Ontario, Canada
• PW

  Paul Wakely, MD

  The Ohio State University
  Columbus, Ohio, United States
• GS

  Gary K. Schwartz, MD

  Director
  Case Comprehensive Cancer Center
  Cleveland, Ohio, United States
• RP

  Raphael E. Pollock, MD, Ph.D

  Director, James Cancer Hospital
  The Ohio State University James Cancer Center
  Columbus, Ohio, United States
• JK

  John Kane, MD

  Rosewell Park Cancer Center
  Buffalo, New York, United States
• SJ

  Steve Jiang, Ph.D

  UT Southwestern
  Dallas, Texas, United States
• AR

  Alan Rogers, MD

  The Ohio State University
  Columbus, Ohio, United States
• YX

  Ying Xiao, Ph.D

  University of Pennsylvania
  Philadelphia, Pennsylvania, United States
• MB

  Marta Batus, MD

  Rush University
  Chicago, Illinois, United States
• 

  Mia Weiss, MD

  Assistant Professor of Medicine
  Washington University
  St Louis, Missouri, United States
• RS

  Rebecca M. Shulman, MD

  Attending Physician
  Fox Chase Cancer Center
  Philadelphia, Pennsylvania, United States
• AJ

  Andrea Johnston, MD

  Oklahoma University
  Oklahoma City, Oklahoma, United States
• 

  Benjamin C. Powers, MD

  Associate Professor, Division of Medical Oncology
  The University of Kansas Health System
  Leawood, Kansas, United States
• UG

  Uma Goyal, MD

  Banner Health
  Glendale, Arizona, United States
• 

  David Konieczkowski, MD, PhD

  Director, Sarcoma Radiation Oncology
  The Ohio State University
  Columbus, Ohio, United States
• 

  Alexandra K. Callan, MD

  Assistant Professor
  UT Southwestern
  Dallas, Texas, United States
• 

  Breelyn A. Wilky, MD (she/her/hers)

  Associate Professor
  University of Colorado School of Medicine
  Aurora, Colorado, United States
• 

  Brian A. Van Tine, MD, PhD

  Professor of Medicine
  Washington University in St Louis School of Medicine
  St. Louis, Missouri, United States
• DW

  Dian Wang, MD, Ph.D

  Rush University
  Chicago, Illinois, United States